FibroBiologics (Direct Listing) FBLG 深 滬
已收盤 08-15 16:00:00 美东时间
0.5735
-0.014
-2.47%
華盛通- 最 高0.5938
- 今 開0.5763
- 成交量 29.34万股
- 最 低 0.5605
- 昨 收 0.588
- 總市值 2194.36万
- 52周最高 4.41
- 市盈率 靜 --
- 換手率 0.77%
- 52周最低 0.5282
- 委 比 62.60%
- 總股本 3826.26万
- 歷史最高 55.00
- 量 比 0.64
- 振 幅 5.66%
- 歷史最低 0.5282
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FibroBiologics Faces Nasdaq Delisting Notice
FibroBiologics, Inc. ( ($FBLG) ) has shared an update. On August 4, 2025, Fibro...
08-09 04:41
Watching FibroBiologics; Zacks Small-Cap Research Gives Stock $11 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08052025_FBLG_Bautz.pdf
08-06 02:38
FibroBiologics, Inc. - Common Stock Q2 EPS $(0.12) Misses $(0.11) Estimate
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 500 percent decrease over earnings of
08-01 05:15
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
FibroBiologics, a biotech company, announced its Q2 2025 financial results, highlighting a $5 million financing round to support a Phase 1/2 trial for diabetic foot ulcers. Key updates include leadership expansion, promising pre-clinical data on psoriasis treatment, and manufacturing confirmation for CybroCell™. Upcoming milestones include initiating the DFU trial in early 2026. Research and development expenses rose to $3.8 million, contributing...
07-31 20:30
D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.
07-29 21:16
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
FibroBiologics, Inc. has filed a patent application for methods to generate multipotent cells from fibroblasts in donor tissue for clinical use. These cells can differentiate into various specialized cell types, offering potential for regenerative treatments and drug development. The innovation addresses challenges in scalable, stable cell production, expanding therapeutic possibilities.
07-28 12:30
FibroBiologics to Present at the Advanced Wound Care Summit USA
**Summary** FibroBiologics, a clinical-stage biotech company, announced that CEO Pete O’Heeron will present at the Advanced Wound Care Summit USA on July 15, 2025, in Boston. The presentation will focus on recent advances in fibroblast-based technology for wound healing and psoriasis. The company's CYWC628 therapy aims to treat diabetic foot ulcers by leveraging natural regenerative processes. A Phase 1/2 trial for this therapy is set to begin l...
07-11 12:30
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
FibroBiologics announced advancements in its cartilage repair program, confirming that its CYWC628 spheroids can be directly differentiated into chondrocytes. This breakthrough enables the company to use its existing master cell bank to develop CybroCell™, an investigational cell therapy for degenerative disc disease (DDD). The milestone supports regulatory filings for a planned Phase I clinical trial and highlights the scalability of its fibrobl...
07-09 12:30
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
FibroBiologics, a clinical-stage biotech公司, invites investors to a webinar on July 10, 2025, at 4:15 p.m. ET, hosted by RedChip Companies. CEO Pete O’Heeron will discuss their fibroblast-based cell therapy platform, which offers scalable, off-the-shelf solutions for chronic, inflammatory, and degenerative conditions. The platform leverages fibroblasts' regenerative and immunomodulatory properties, which are abundant, immune-privileged, and cost-e...
07-07 20:35
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
